1. Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer. 2016;16: 330.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; doi:10.3322/caac.21492
3. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol. 2007;25: 1705–1712.
4. OuYang P-Y, Zhang L-N, Lan X-W, Xie C, Zhang W-W, Wang Q-X, et al. The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis. Br J Cancer. 2015;112: 1554–1561.
5. Li CH, Haider S, Shiah Y-J, Thai K, Boutros PC. Sex Differences in Cancer Driver Genes and Biomarkers. Cancer Res. 2018;78: 5527–5537.
6. Wands J. Hepatocellular carcinoma and sex. N Engl J Med. 2007;357: 1974–1976.
7. Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016;139: 1534–1545.
8. Ladenheim MR, Kim NG, Nguyen P, Le A, Stefanick ML, Garcia G, et al. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterol. 2016;3: e000107.
9. Gilks WP, Abbott JK, Morrow EH. Sex differences in disease genetics: evidence, evolution, and detection. Trends Genet. 2014;30: 453–463.
10. Morrow EH. The evolution of sex differences in disease. Biol Sex Differ. 2015;6: 5.
11. Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, et al. Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. Cancer Cell. 2016;29: 711–722.
12. Gong J, Mei S, Liu C, Xiang Y, Ye Y, Zhang Z, et al. PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. Nucleic Acids Res. 2018;46: D971–D976.
13. Behrens G, Winkler TW, Gorski M, Leitzmann MF, Heid IM. To stratify or not to stratify: power considerations for population-based genome-wide association studies of quantitative traits. Genet Epidemiol. 2011;35: 867–879.
14. Dimas AS, Nica AC, Montgomery SB, Stranger BE, Raj T, Buil A, et al. Sex-biased genetic effects on gene regulation in humans. Genome Res. 2012;22: 2368–2375.
15. Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 2016;375: 1109–1112.
16. Webster TH, Couse M, Grande BM, Karlins E, Phung TN, Richmond PA, et al. Identifying, understanding, and correcting technical biases on the sex chromosomes in next-generation sequencing data [Internet]. bioRxiv. 2018. p. 346940. doi:10.1101/346940
17. Andrews S. FastQC A Quality Control tool for High Throughput Sequence Data. In: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ [Internet]. 2010. Available: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
18. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30: 2114–2120.
19. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12: 357–360.
20. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30: 923–930.
21. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20: 1297–1303.
22. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43: 491–498.
23. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43: 11.10.1–33.
24. Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, et al. The UCSC Genome Browser Database: update 2006. Nucleic Acids Res. 2006;34: D590–8.
25. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26: 139–140.
26. Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15: R29.
27. Xia J, Gill EE, Hancock REW. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat Protoc. 2015;10: 823–844.
28. Leek JT, Storey JD. Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis. PLoS Genet. 2007;3: e161.
29. Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat Protoc. 2012;7: 500–507.
30. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics. 2012;28: 3326–3328.
31. Delaneau O, Ongen H, Brown AA, Fort A, Panousis N, Dermitzakis E. A complete tool set for molecular QTL discovery and analysis. bioRxiv. 2016; doi:10.1101/068635
32. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45: 580–585.
33. Cavalcante RG, Sartor MA. annotatr: genomic regions in context. Bioinformatics. 2017;33: 2381–2383.
34. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods. 2012;9: 215–216.
35. Kukurba KR, Parsana P, Balliu B, Smith KS, Zappala Z, Knowles DA, et al. Impact of the X Chromosome and sex on regulatory variation. Genome Res. 2016;26: 768–777.
36. Gho JW-M, Ip W-K, Chan KY-Y, Law PT-Y, Lai PB-S, Wong N. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest. Cancer Res. 2008;68: 6743–6751.
37. Wang W, Huang P, Zhang L, Wei J, Xie Q, Sun Q, et al. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci. 2013;104: 1523–1531.
38. Shen Y, Li X, Su Y, Badshah SA, Zhang B, Xue Y, et al. HAMP Downregulation Contributes to Aggressive Hepatocellular Carcinoma via Mechanism Mediated by Cyclin4-Dependent Kinase-1/STAT3 Pathway [Internet]. Diagnostics. 2019. p. 48. doi:10.3390/diagnostics9020048
39. Liu F, Zhu C, Huang X, Cai J, Wang H, Wang X, et al. A low level of GPR37 is associated with human hepatocellular carcinoma progression and poor patient survival. Pathol Res Pract. 2014;210: 885–892.
40. Jo J-C, Choi EK, Shin J-S, Moon J-H, Hong S-W, Lee H-R, et al. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity. Mol Cancer Ther. 2015;14: 2613–2622.
41. Xiao P, Long X, Zhang L, Ye Y, Guo J, Liu P, et al. Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells. Oncoimmunology. 2018;7: e1440166.
42. Lasseigne BN, Burwell TC, Patil MA, Absher DM, Brooks JD, Myers RM. DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Med. 2014;12: 235.
43. Gaykalova DA, Zizkova V, Guo T, Tiscareno I, Wei Y, Vatapalli R, et al. Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC. Oncotarget. 2017;8: 15349–15363.
44. Liu Y, Zheng P. CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. Trends Immunol. 2007;28: 315–320.
45. Gou Q, Gong X, Jin J, Shi J, Hou Y. Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy. Oncotarget. 2017;8: 60704–60709.
46. Mayer IA, Arteaga CL. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu Rev Med. 2016;67: 11–28.
47. Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, et al. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Crit Rev Oncol Hematol. 2017;113: 256–267.
48. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16: 15–31.
49. Demir IE, Tieftrunk E, Schorn S, Friess H, Ceyhan GO. Nerve growth factor & TrkA as novel therapeutic targets in cancer. Biochim Biophys Acta. 2016;1866: 37–50.
50. Zhang Y-L, Wang R-C, Cheng K, Ring BZ, Su L. Roles of Rap1 signaling in tumor cell migration and invasion. Cancer Biol Med. 2017;14: 90–99.
51. Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, et al. Prospects of IL-2 in Cancer Immunotherapy. Biomed Res Int. 2018;2018: 9056173.
52. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15: 540–555.
53. Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10: 473–510.
54. Mehta A, Herrera H, Block T. Chapter Seven - Glycosylation and Liver Cancer. In: Drake RR, Ball LE, editors. Advances in Cancer Research. Academic Press; 2015. pp. 257–279.
55. Liang K-H, Yeh C-T. O-glycosylation in liver cancer: Clinical associations and potential mechanisms. Liver Research. 2017;1: 193–196.
56. Villegas SN, Gombos R, García-López L, Gutiérrez-Pérez I, García-Castillo J, Vallejo DM, et al. PI3K/Akt Cooperates with Oncogenic Notch by Inducing Nitric Oxide-Dependent Inflammation. Cell Rep. 2018;22: 2541–2549.
57. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, et al. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene. 2010;29: 2488–2498.
58. Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 2013;24: 766–776.
59. Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia [Internet]. Cellular Signalling. 2014. pp. 149–161. doi:10.1016/j.cellsig.2013.09.021
60. Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H, et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol. 2011;7: 787–793.
61. Wang G-L, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev. 2004;18: 912–925.
62. Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14: 1483–1496.
63. Baar EL, Carbajal KA, Ong IM, Lamming DW. Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice. Aging Cell. 2016;15: 155–166.